Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Notified -...

Azurity Pharmaceuticals Names Ogilvy Health as PR and Marketing Agency of Record to Drive Strategic Brand Repositioning and Enhance Market Visibility

Azurity Pharmaceuticals Names Ogilvy Health as PR and Marketing Agency of Record to Drive Strategic Brand Repositioning and Enhance Market Visibility

Notified -...

Persephoni Launches Strategic Sponsorship with American Cancer Society’s BrightEdge to Accelerate Oncology Innovation

Persephoni Launches Strategic Sponsorship with American Cancer Society’s BrightEdge to Accelerate Oncology Innovation

Notified -...

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

...

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

Notified -...

menu
menu